Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASC 618

Next Previous
Drug Profile

ASC 618

Alternative Names: Adeno-associated viral vector haemophilia A gene therapy - ASC Therapeutics; ASC-618; CRISPR/cas9 edited human factor VIII - ASC Therapeutics

Latest Information Update: 02 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ASC Therapeutics
  • Class Antihaemorrhagics; Blood coagulation factors; Gene therapies
  • Mechanism of Action Factor VIII replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Haemophilia A

Most Recent Events

  • 31 Aug 2022 Phase-I/II clinical trials in Haemophilia A in USA (Parenteral) (NCT04676048)
  • 16 May 2022 ASC 618 receives Orphan Drug status for Haemophilia A in Europe prior to May 2022
  • 29 Mar 2022 ASC 618 receives Fast Track designation for Haemophilia A [Parenteral] in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top